Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01089621
Other study ID # 12865
Secondary ID F1J-MC-HMGE
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date March 2010
Est. completion date August 2010

Study information

Verified date October 2019
Source Eli Lilly and Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the possibility of conducting a larger study in adolescents with fibromyalgia syndrome.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date August 2010
Est. primary completion date August 2010
Accepts healthy volunteers No
Gender All
Age group 13 Years to 17 Years
Eligibility Inclusion Criteria:

- Meet criteria for juvenile primary fibromyalgia syndrome as defined by Yunus and Masi.

- Have a score of greater than or equal to 40mm on item 3 of the Pediatric Pain Questionnaire at screening and treatment baseline.

- Female patients must have a negative pregnancy test at baseline and must agree to abstain from sexual activity or use a reliable method of birth control.

- Patients must be capable of swallowing study drug whole.

- Patients must have venous access sufficient to allow blood sampling and be compliant with blood draws as per the protocol.

Exclusion Criteria:

- Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device, or off-label use of a drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

- Have pain symptoms related to traumatic injury, past surgery, structural bone or joint disease (such as osteoarthritis, bursitis, tendonitis), or regional pain syndrome that will interfere with the interpretation of outcome measures.

- Have a confirmed current or previous diagnosis of rheumatoid arthritis, inflammatory arthritis, or infectious arthritis, or an autoimmune disease.

- Have any primary Axis diagnosis OTHER than major depressive disorder (MDD) and/or generalized disorder (GAD) as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), currently or within the past year. Patients with specific phobias may participate in this study.

- Have any lifetime DSM-IV Axis I diagnosis of psychosis, bipolar disorder, or schizoaffective disorder.

- Have any DSM-IV Axis II disorder which, in the judgment of the investigator, would interfere with protocol compliance.

- Have a history of substance abuse or dependence within the past year, excluding nicotine and caffeine.

- Have a positive urine drug screen for any substances of abuse or excluded medication.

- Have a family history of 1 or more first-degree relatives (parents or siblings) with diagnosed bipolar I disorder.

- Have a significant suicide attempt within 1 year of screening or are currently at suicidal risk in the opinion of the investigator.

- Have a weight less than 20 kg at any screening phase.

- Have initiated, stopped, or changed the type or intensity of psychotherapy within 3 months prior to screening.

- Have a history of seizure disorder (other than febrile seizures).

- Have abnormal thyroid-stimulating hormone (TSH) concentrations. Patients with hypothyroidism who have been treated on a stable dose of thyroid supplement for at least the past 3 months and have medically appropriate TSH concentrations, and are clinically euthyroid may participate in the study.

- Have acute liver injury or sever cirrhosis.

- Have previously taken duloxetine.

- Have a serious or unstable medical illness.

- Have initiated or discontinued hormone therapy within the previous 3 months.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Duloxetine
30 mg to 120 mg administered orally, daily for 12 weeks

Locations

Country Name City State
United States For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Canton Ohio
United States For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Cincinnati Ohio
United States For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fairfield Connecticut
United States For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Oklahoma City Oklahoma
United States For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Phoenix Arizona
United States For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Portland Oregon
United States For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Saint Louis Missouri
United States For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Salt Lake City Utah
United States For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Staten Island New York

Sponsors (1)

Lead Sponsor Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of enrollment 6 months of enrollment
Primary Rate of retention 12 weeks of treatment
Secondary Change in score from baseline to endpoint on the Pediatric Pain Questionnaire (PPQ) Baseline, 12 weeks
Secondary Change in score from baseline to endpoint on the Brief Pain Inventory (BPI) modified short form severity Baseline, 12 weeks
Secondary Change in score from baseline to endpoint on the Clinical Global Impression of Severity, overall (CGI-Severity: overall) scale Baseline, 12 weeks
Secondary Endpoint score of Patient Global Impression of Improvement (PGI-I) scale 12 weeks
Secondary Change in score from baseline to endpoint on the Functional Disability Inventory - child version (FDI-child) scale Baseline, 12 weeks
Secondary Change in score from baseline to endpoint on the Functional Disability Inventory - parent version (FDI-parent) scale Baseline, 12 weeks
Secondary Change in score from baseline to endpoint on the Clinical Global Impression of Severity for Mental Illness (CGI-mental illness) scale Baseline, 12 weeks
Secondary Change in score from baseline to endpoint on the Children's Depression Inventory (CDI) Baseline, 12 weeks
Secondary Change in score from baseline to endpoint on the Multidimensional Anxiety Scale for Children (MASC) Baseline, 12 weeks
Secondary Columbia Suicide-Severity Rating Scale (CSSRS) During 12 weeks of treatment
Secondary Change in score from baseline to endpoint on the Pediatric Quality of Life Inventory - teen report (PedsQL) Baseline, 12 weeks
Secondary Number of patients with treatment emergent abnormal laboratory values During 12 weeks of treatment
Secondary Change from baseline to endpoint in blood pressure Baseline, 12 weeks
Secondary Change from baseline to endpoint in heart rate Baseline, 12 weeks
Secondary Change from baseline to endpoint in weight Baseline, 12 weeks
Secondary Change from baseline to endpoint in height Baseline, 12 weeks
Secondary Number of patients with treatment emergent abnormal electrocardiogram During 12 weeks of treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05659862 - Digitally Assisted Behavioral Physical Activity Intervention in Fibromyalgia N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT03042728 - Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program N/A
Recruiting NCT06097091 - Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia N/A
Recruiting NCT04554784 - Effectiveness of Bowen Therapy for Pain Management in Patients With Fibromyalgia N/A
Completed NCT03300635 - Metabolism, Muscle Function and Psychological Factors in Fibromyalgia N/A
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT03166995 - Postural Exercises in Women With Fibromyalgia N/A
Completed NCT03227952 - Sensory Stimulation in Fibromyalgia N/A
Recruiting NCT06237595 - Vagus Nerve Stimulation in Fibromyalgia N/A
Completed NCT01888640 - Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST) N/A
Completed NCT03641495 - Pain Education and Therapeutic Exercise for Fibromyalgia N/A
Recruiting NCT05581628 - FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
Active, not recruiting NCT05128162 - Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia Phase 2
Completed NCT04674878 - Comparison of Muscle Energy Techniques and Breathing Exercises for Functional Improvement in Fibromyalgia N/A
Active, not recruiting NCT04084795 - Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia N/A
Completed NCT03129906 - Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients N/A
Completed NCT05058911 - Exposure-based Cognitive Behavior Therapy vs Traditional Cognitive Behavior Therapy for Fibromyalgia N/A
Recruiting NCT04571528 - Effectiveness of VIRTUAL FIBROWALK STUDY N/A
Recruiting NCT04571853 - New Educational Tool for FM N/A